News

Public · Published

As Ebola Spreads to Multiple Countries, the Importance of NV-387 Oral Gummies Treatment Cannot be Understated - Phase II Clinical Trial Advancing Towards the Second Part, Says NanoViricides

NanoViricides said its Phase IIA Ebola trial of NV-387 oral gummies in the DRC is progressing, with enrollment begun September 23, 2026. The first part uses about 20 patients and measures 28-day survival, after which the drug is expected to advance to Phase IIB.

Published:

Updated:

What happened

NanoViricides said its Phase IIA Ebola trial of NV-387 oral gummies in the DRC is progressing, with enrollment begun September 23, 2026. The first part uses about 20 patients and measures 28-day survival, after which the drug is expected to advance to Phase IIB.

Confirmed

Global impact / market context

Success would move NanoViricides closer to a treatment taken by mouth rather than injection, which could simplify care in outbreak areas. The trial remains early and small, so results are uncertain and may not translate into approval, revenue, or profit per sale.

Analyst inference

Ebola outbreaks can spread across borders and impose heavy costs for containment and response, which the company cites as supporting urgency. For investors, this is a single small clinical program, so trial timing and survival results are likely the main drivers rather than broad sector trends.

Analyst inference

What to watch

  1. Phase IIA needs about 20 patients, and it finishes when the last enrolled person completes 28 days, so enrollment pace and that final 28-day check set the timing. Confirmed
  2. The company expects the trial to continue into Phase IIB once Phase IIA is completed, but this is a stated plan and not a confirmed start date or result. Proposed
  3. Watch whether the 28-day survival endpoint is met and whether regulators accept the oral gummy format, because either could affect future capital spending, cash available, and investor positioning. Analyst inference

Evidence